SCHEMBL5764902

SCHEMBL5764902

CCc1nc(Cc2cccc(F)c2)sc1C1CCNCC1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 4/20 0.47
HTR6 P50406 4/20 0.43
SLC6A2 P23975 4/20 0.40
SLC6A3 Q01959 4/20 0.40
HTR2C P28335 1/20 0.39
HTR2B P41595 1/20 0.39
GPR52 Q9Y2T5 1/20 0.37
MET P08581 1/20 0.37
SLC6A4 P31645 3/20 0.36
GABRA1 P14867 1/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
CDK9 P50750 3/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35
HTR2A P28223 1/20 0.35
HTR7 P34969 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5762631 0.90 CCR5 (0.41) CCR5SLC6A2HTR2CSLC6A4GABRA1
SCHEMBL5764687 0.89 CCR5 (0.38) CCR5HTR6SLC6A2SLC6A3SLC6A4
SCHEMBL5763298 0.88 HTR2C (0.43) CCR5HTR6SLC6A2SLC6A3HTR2C
SCHEMBL5765101 0.87 HTR6 (0.50) HTR6SLC6A2SLC6A3HTR2CHTR2B
SCHEMBL5764323 0.87 HTR6 (0.43) CCR5HTR6HTR2CHTR2BGPR52
SCHEMBL5764678 0.86 CCR5 (0.40) CCR5SLC6A2SLC6A3HTR2CHTR2B
SCHEMBL5764303 0.86 HTR6 (0.46) CCR5HTR6SLC6A2HTR2CHTR2B
SCHEMBL5762735 0.86 GABRA1 (0.47) CCR5SLC6A2SLC6A3SLC6A4GABRA1
SCHEMBL5764779 0.85 HTR6 (0.40) CCR5HTR6GABRA1GABRG2GABRB3
Hydrochloric Acid SCHEMBL5764059 0.85 GABRA1 (0.46) CCR5SLC6A2SLC6A3SLC6A4GABRA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192133-B1 N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2006-11-02 EP disclosed
US-6593346-B2 Substituted 3-(piperidin-1-ylmethyl)cyclopentylamines, useful as modulators of the chemokine receptors CCR-5 and/or CC R-3. MERCK & CO. INC. 2003-07-15 US disclosed
US-6538002-B1 In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3. as antiinflammatory agents MERCK & CO., INC. 2003-03-25 US disclosed
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2002-08-29 US disclosed
US-6432981-B1 BLOCKS HUMAN IMMUNODEFICIENCY VIRUS (HIV) FROM ENTERING CELLS; AUTOIMMUNE DISEASES; ANTIALLERGENS, ANTIINFLAMMATORY AND ANTIASTHMATIC AGENTS MERCK & CO., INC. 2002-08-13 US disclosed
US-6358979-B1 FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS MERCK & CO., INC. 2002-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity CCR1, CCR3, CCR5 CCR5 3/4885HTR6 1057/4885SLC6A2 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.